Search
forLearn
5 / 801 resultsResearch
5 / 1000+ results
research Pengaruh Terapi Kombinasi 5 Titik Akupunktur Terhadap Penurunan Jumlah Rambut Rontok (Alopecia Androgenetic) Pada Wanita Usia 31-50 Tahun
Acupuncture therapy significantly reduced hair loss in women aged 31-50 with female pattern hair loss.
research An epidemiological study of androgenic alopecia in 3114 Korean patients
Smoking and drinking worsened hair loss in men with genetic hair loss, while eating and sleeping habits didn't; genetics played a bigger role than environment in hair loss.
research Melatonin and hair physiology: reasons and clinical efficacy data as a topical treatment of androgenic alopecia
Melatonin applied to the scalp helps increase hair density in people with early hair loss.
research Melatonina y fisiología capilar: razones y datos de eficacia clínica como tratamiento
Melatonin applied to the scalp helps treat early-stage hair loss in men and women.
research S1-Leitlinie Long-/Post-COVID
The guideline offers current advice for diagnosing and treating Long- and Post-COVID symptoms.
Community Join
5 / 1000+ resultscommunity Kintor starts a new Phase 3 for Pyri... (1+ year)
The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.
community Kintor announcement about pyrilutamide phase 3 results in CHINA
Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.
community Kintor has released an investor relations memo regarding Chinese Phase III trials for Pyrilutamide
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
community Kintors interim report from 9-2-24 for everyone whos interested
Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.
community Kintor long term safety phase 3
Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.